Innoplexus - a Partex Company
The expert in AI technology for drug discovery and development.
The expert in AI technology for drug discovery and development.
Innoplexus, founded in 2015 and headquartered in Germany, aims to transform decision-making processes for organizations through the utilization of cutting-edge technologies such as Artificial Intelligence, Blockchain, and advanced analytics. The company's slogan emphasizes its commitment to using AI, Blockchain, and advanced analytics to enable continuous decision-making from both structured and unstructured data. With a focus on industries including Analytics, Blockchain, Information Technology, and Pharmaceuticals, Innoplexus leverages data from both private and public sources to provide faster, deeper, and more expansive insights, ultimately enabling continuous decision-making. The company recently secured a Series C investment on 24 April 2019 from prominent investors including ATAI Life Sciences, EOS VC, Finlab AG, and Block.one. Innoplexus' innovative approach and the support from reputable investors position it as a promising player in the evolving landscape of AI and analytics in the healthcare and technology sectors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | Unknown | 4 |
|
24 Apr 2019 |
| Venture Round | Unknown | 1 | Christian Angermayer | 03 Mar 2017 |
| Venture Round | Unknown | 1 | HCS Beteiligungsgesellschaft | 05 Dec 2016 |
No recent news or press coverage available for Innoplexus - a Partex Company.
We care about your data, and we'd love to use cookies make your experience better.
